- |||||||||| Enrollment change, Trial completion date, Trial termination: DTCU: Dietary Treatment for Chronic Urticaria (clinicaltrials.gov) - Aug 2, 2018
P=N/A, N=8, Terminated, Recruiting --> Completed N=78 --> 8 | Trial completion date: Dec 2017 --> Jul 2018 | Recruiting --> Terminated; Unable to recruit subjects, patients want active treatment instead of placebo.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Trial completion: Cold Contact Urticaria Treatment With Rilonacept (clinicaltrials.gov) - Jul 17, 2018 P2, N=20, Completed, N=78 --> 8 | Trial completion date: Dec 2017 --> Jul 2018 | Recruiting --> Terminated; Unable to recruit subjects, patients want active treatment instead of placebo. Active, not recruiting --> Completed
- |||||||||| Ruconest (conestat alfa) / SOBI, Pharming Group
Trial completion, Trial completion date, Trial primary completion date: Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients (clinicaltrials.gov) - Jul 13, 2018 P2, N=20, Completed, Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Dec 2017 --> Jul 2017 | Trial primary completion date: Dec 2017 --> Jul 2017
- |||||||||| Xolair (omalizumab) / Roche, Novartis
Trial completion: Efficacy and Safety Study of Omalizumab (Xolair (clinicaltrials.gov) - Oct 24, 2017 P2, N=20, Completed, Recruiting --> Completed | Trial primary completion date: May 2015 --> Jun 2016 Enrolling by invitation --> Completed
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Trial initiation date, IO biomarker: Study of Tocilizumab to Treat Polymyalgia Rheumatica (clinicaltrials.gov) - Mar 15, 2017 P2a, N=10, Completed, Active, not recruiting --> Completed | N=250 --> 473 Active, not recruiting --> Completed | Initiation date: Jul 2011 --> Apr 2011
- |||||||||| Trial completion, Enrollment change: UCT-V: Validation of an Urticaria Control Test (clinicaltrials.gov) - Jan 6, 2017
P=N/A, N=120, Completed, Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Completed | N=100 --> 120
- |||||||||| Trial completion, Enrollment change: UCT-D: Development of an Urticaria Control Test (clinicaltrials.gov) - Jan 6, 2017
P=N/A, N=508, Completed, Recruiting --> Completed | N=100 --> 120 Recruiting --> Completed | N=300 --> 508
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Trial primary completion date: Cold Contact Urticaria Treatment With Rilonacept (clinicaltrials.gov) - Jan 6, 2017 P2, N=20, Recruiting, Recruiting --> Completed | N=300 --> 508 Trial primary completion date: Feb 2017 --> Dec 2017
- |||||||||| Trial completion, Trial primary completion date: SOS AOH: A Call Center During HAE Attacks (SOS HAE) (clinicaltrials.gov) - Dec 13, 2016
P4, N=200, Completed, Trial primary completion date: Feb 2017 --> Dec 2017 Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Sep 2016
- |||||||||| Humira (adalimumab) / AbbVie
Trial completion, Enrollment change: Efficacy of Humira in Behcet Patients With Arthritis (clinicaltrials.gov) - Oct 26, 2016 P3, N=9, Completed, Recruiting --> Active, not recruiting Recruiting --> Completed | N=15 --> 9
- |||||||||| Ilaris (canakinumab) / Novartis
Trial completion, Enrollment change, Trial primary completion date: Canakinumab for Pyoderma Gangrenosum (clinicaltrials.gov) - Sep 27, 2016 P2, N=5, Completed, Trial primary completion date: Sep 2016 --> Dec 2016 Recruiting --> Completed | N=10 --> 5 | Trial primary completion date: Aug 2012 --> Aug 2014
- |||||||||| bilastine / Generic mfg.
Trial completion, Trial primary completion date: Bilastine Updosing in Chronic Spontaneous Urticaria (clinicaltrials.gov) - Aug 26, 2016 P3, N=30, Completed, Trial primary completion date: Sep 2016 --> Dec 2016 Recruiting --> Completed | Trial primary completion date: Jun 2016 --> Mar 2016
- |||||||||| gevokizumab (S 78989) / Novartis
Enrollment change, Trial termination, Trial primary completion date: An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum (clinicaltrials.gov) - Apr 27, 2016 P3, N=16, Terminated, N=100 --> 15 | Enrolling by invitation --> Terminated | Trial primary completion date: Oct 2018 --> Feb 2016 N=58 --> 16 | Recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Mar 2016
|